Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis

NCT03591887 is registered in ClinicalTrials.gov with Affibody as lead sponsor.

NCT NCT03591887
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03591887 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Randomized, Parallel Group, Placebo-controlled, Double-blinded, Dose-finding Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis
Lead sponsor
Affibody
Phase
Phase 2
Overall status
Completed
Start date
March 7, 2018
Completion date
December 3, 2021
Enrollment
108 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis